At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TYRA Tyra Biosciences, Inc.
Pre-Mkt 10-12 07:14:52 EDT
19.94
-0.03
-0.15%
盘前19.00
-0.94-4.71%
07:02 EDT
High20.59Low19.73Vol649.44K
Open19.93D1 Closing19.97Amplitude4.29%
Mkt Cap1.37BTradable Cap797.71MTotal Shares68.76M
T/O13.10MT/O Rate1.62%Tradable Shares40.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tyra Biosciences Price Target Cut to $40.00/Share from $50.00 by Oppenheimer
Dow Jones  ·  09-23
Tyra Biosciences Price Target Cut to $40.00/Share from $50.00 by Oppenheimer
Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer
TIPRANKS  ·  09-22
Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer
Tyra Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $29 from $30
THOMSON REUTERS  ·  09-22
Tyra Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $29 from $30
Tyra Bioscience announces $400M equity financing offering
TIPRANKS  ·  09-15
Tyra Bioscience announces $400M equity financing offering
Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus
Benzinga Earnings  ·  09-15
Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus
Tyra Biosciences Shares up 4.4% Premarket After $400 Mln Equity Raise
THOMSON REUTERS  ·  09-14
Tyra Biosciences Shares up 4.4% Premarket After $400 Mln Equity Raise
Tyra Biosciences Rises After $400 Mln Equity Raise
Reuters  ·  09-14
Tyra Biosciences Rises After $400 Mln Equity Raise
Tyra Biosciences Prices USD 400 Million Stock, Pre-Funded Warrant Offering at USD 22.03 Per Share
Reuters  ·  09-14
Tyra Biosciences Prices USD 400 Million Stock, Pre-Funded Warrant Offering at USD 22.03 Per Share
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  09-14
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences, - Announces Pricing of 9,079,000 Common Shares at $22.03 Per Share
THOMSON REUTERS  ·  09-14
Tyra Biosciences, - Announces Pricing of 9,079,000 Common Shares at $22.03 Per Share
Tyra Biosciences Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  09-14
Tyra Biosciences Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing
Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead
TIPRANKS  ·  09-12
Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead
Tyra Biosciences Director Rehan Verjee Buys $20,000 of Common Shares
Reuters  ·  09-12
Tyra Biosciences Director Rehan Verjee Buys $20,000 of Common Shares
Tyra Biosciences Price Target Maintained with a $53.00/Share by Wedbush
Dow Jones  ·  09-10
Tyra Biosciences Price Target Maintained with a $53.00/Share by Wedbush
Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright
TIPRANKS  ·  09-10
Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright
U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs
Reuters  ·  09-10
U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Dow Jones  ·  09-09
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
Dow Jones  ·  09-09
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software
Reuters  ·  09-09
U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software
Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations
Reuters  ·  09-09
Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations
No data available

Introduction

Company Name.
Tyra Biosciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Issue price:
--